CNDO-109
/ Fortress
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 31, 2018
A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
(PubMed, Biol Blood Marrow Transplant)
- "Before CNDO-109-NK cell administration, patients were treated with lymphodepleting fludarabine/cyclophosphamide. This trial establishes that CNDO-109-NK cells generated from related HLA-haploidentical donors, cryopreserved, and then safely administered to AML patients with transient persistence without exogenous cytokine support. Three durable complete remissions of 32.6 to 47.6+ months were observed, suggesting additional clinical investigation of CNDO-109-NK cells for patients with myeloid malignancies, alone or in combination with additional immunotherapy strategies, is warranted."
Clinical • Journal • P1 data
1 to 1
Of
1
Go to page
1